Navigation Links
Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
Date:2/24/2011

esults may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, our ability to successfully integrate Inovio and VGX Pharmaceuticals, the impact of go
'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
2. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
5. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
6. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
7. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
8. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
9. Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2010 Financial Results
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented ... that a therapy being developed by Hera Therapeutics Inc. combats ... 70 percent of all cervical cancer. When tested ... of HPV-16, HPV-18 and HPV-11 cells, according to Louise ... who presented the findings at the Seattle ...
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, is ... third international medical cannabis conference taking place at ... France , on October 22, 2014.  The ... stakeholders, such as researchers, health professionals, and patients, ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... 2011 Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... unit, SAFC® ( www.safcglobal.com ), is introducing a novel ... (CHO) cell line. Designed for use in the production ... the first commercially available glutamine synthetase (GS) knockout CHO ...
... YORK, Oct. 27, 2011 Reportlinker.com ... report is available in its catalogue: ... Reimbursement Outlook: Optimizing price and market ... http://www.reportlinker.com/p0165652/Pharma-Pricing-and-Reimbursement-Outlook-Optimizing-price-and-market-access-in-a-recessionary-climate.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Health_Insurance ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 2Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 3Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 4Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 5
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... that teaches readers how they can use natural methods ... for years has caught the attention of Shane Michaels, ... only a condition that affects the skin, it can ... suffer from it,” reports Michaels. “The intense itching and ...
(Date:8/22/2014)... receptor (EGFR) mutations found in the circulating free tumor ... lung cancer (NSCLC) patients correlates well with the EGFR ... kinase inhibitor (TKI) therapy is approved for EGFR activating ... for determining mutation status is with DNA derived directly ... available. A more abundant and less invasive source of ...
(Date:8/22/2014)... Advancements in ultrasound technologies make ... due to their cost-effectiveness, non-invasiveness, and absence of ... such as the evolution of wireless transducers and ... market moving throughout 2014 and beyond. Such Ultrasound’s ... only the point-of-care (POC) testing in hospital settings, ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 CarePoint ... specialist in Internal Medicine, Geriatrics, Hospice and Palliative ... CarePoint Health Medical Group. Their system welcomes Dr. ... and experienced physicians comprise CarePoint Health Medical Group, ... in Hudson County, representing a wide range of ...
(Date:8/22/2014)... West Orange, NJ. August 22, 2014. A ... shows that persons with multiple sclerosis (MS) may ... cognitive rehabilitation. The study was epublished ahead of ... (Yael Goverover, Helen Genova, Hali Griswold, Nancy D. ... awareness in persons with multiple sclerosis doi: 10.3233/NRE-141113). ...
Breaking Medicine News(10 mins):Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... for study of human genetics and disease , THURSDAY, Aug. ... genes are responsible for all seven types of coats found ... like Bo, President Obama,s pooch, or long-haired like Lassie, variations ... to a U.S. National Institutes of Health study published online ...
... disparity in prostate cancer stage at diagnosis has decreased ... published online August 27 in the Journal of ... from the Surveillance, Epidemiology, and End Results (SEER) program, ... New Jersey and the University of Medicine and Dentistry ...
... RICHMOND, Va., Aug. 27 The ,Help is Here ... week of August 31 - September 3 at various cities ... on programs that provide prescription medicines for free or nearly ... - and having risen for 26 straight months - the ...
... ,fatostatin, is still in early stages , THURSDAY, Aug. 27 ... to have the power to turn off fat production, potentially ... injected with the chemical, known as fatostatin, didn,t get fatter ... team said. , But don,t run out and ask ...
... , MINNEAPOLIS, Aug. 27 In August 1989, a ... to become one of the first child advocacy centers in the ... organization, improving the way child abuse is investigated around the world. ... medical examinations for children and vulnerable adults who report sexual abuse ...
... The Radiological Society of North America (RSNA) reaffirmed ... a study and accompanying perspective on radiation dose from ... of Medicine (NEJM). In "Exposure to ... M.D., M.Sc., and colleagues reported that imaging procedures are ...
Cached Medicine News:Health News:Benji, Marley or Bo: Three Genes Dictate Dog's Coat 2Health News:Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 4Health News:Fat-Fighting Chemical Holds Promise 2Health News:Minneapolis-based CornerHouse Marks 20th Anniversary of Helping Sexually Abused Children Around the World 2Health News:Minneapolis-based CornerHouse Marks 20th Anniversary of Helping Sexually Abused Children Around the World 3Health News:Radiologists, medical physicists work to make imaging procedures safer 2
... The 1081 is an all-in-one drape ... The drape includes a pouch with filter ... finger cot. 64 inches (164cm) TUR ... Elastic aperture, Neoprene finger cot, Fluid collection ...
... Both the Penilab IV and the Penilab V ... studies. Model 1060 is similar to the Model ... nor can one be added later. The Penilab ... including all of the accessories you'll need to get ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... II SP MRI-Compatible Anesthesia System is perfect for ... than one type of anesthetic agent. , ... due to its wider stance, has a larger ... bellows assembly is utilized in both the Integra ...
Medicine Products: